A Review of Drug Options for High Grade Meningiomas That Come Back
Original title: Advances in Pharmacological Therapy for Recurrent High-Grade Meningiomas.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This looks across many earlier studies rather than running a new one.
This is a summary of where the research stands, not a new result or a treatment you can count on today.
The short version
Doctors looked at all the drug treatments tried so far for aggressive meningiomas that return, and found none are proven yet.
What was studied. Researchers searched medical databases and trial records up to August 2025. They gathered studies on chemotherapy, targeted drugs, and immune therapy for WHO grade 2 and 3 meningiomas that came back after treatment.
What they found. Standard chemotherapy did little to help people live longer. It is mostly used to ease symptoms. Targeted drugs did better. With bevacizumab, the time before the tumor grew again stretched to 12 to 18 months in early trials. With immune drugs called PD-1 inhibitors, up to 48% of people went 6 months without their tumor growing in early studies. Newer immune approaches like CAR-T, virus therapy, and personalized vaccines showed early signs of promise.
What this means, and what it doesn't
What it could mean: If your meningioma has come back after surgery and radiation, there are drugs being tried. Some show real activity against these tumors. Your doctor may already offer bevacizumab, or may suggest a trial. It is worth asking what options fit your tumor.
What it doesn't mean: This is a review of other people's studies. It is not a new treatment and not a cure. No drug here is proven to work for these tumors. The trials so far were small, and they were run in different ways, so the results are hard to compare. Tumors also differ a lot from person to person. Most of these drugs are still being tested and are not standard care.
Source: PubMed, July 24, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.